ACS Publications. Most Trusted. Most Cited. Most Read

OR SEARCH CITATIONS

My Activity
Publications
CONTENT TYPES

Figure 1Loading Img
Download Hi-Res ImageDownload to MS-PowerPointCite This:J. Med. Chem. 2013, 56, 23, 9369-9402
RETURN TO ISSUEPerspectiveNEXT

Inhibition of Hypoxia-Inducible Factor Prolyl Hydroxylase Domain Oxygen Sensors: Tricking the Body into Mounting Orchestrated Survival and Repair Responses

View Author Information
Janssen Pharmaceutical Research & Development, LLC, 3210 Merryfield Row, San Diego, California 92121, United States
*Phone: +1 858 320-3340. E-mail: [email protected]
Cite this: J. Med. Chem. 2013, 56, 23, 9369–9402
Publication Date (Web):August 27, 2013
https://doi.org/10.1021/jm400386j
Copyright © 2013 American Chemical Society
Request reuse permissions

    Article Views

    5162

    Altmetric

    -

    Citations

    129
    LEARN ABOUT THESE METRICS
    Read OnlinePDF (2 MB)
    Get e-Alerts
    SUBJECTS:

    Abstract

    Abstract Image

    Hypoxia-inducible factor (HIF) is an oxygen-sensitive dimeric transcription factor that responds to pathophysiologically low O2 tensions via up-regulation, which leads to an orchestrated biological response to hypoxia. The HIF prolyl hydroxylase domain (PHD) enzymes are non-heme, iron-containing dioxygenases requiring for activity both molecular oxygen and 2-oxoglutarate that, under normoxia, selectively hydroxylate proline residues of HIF, initiating proteosomal degradation of the latter. The dependence of HIF protein levels on the concentration of O2 present, mediated by the PHD enzymes, forms the basis for one of the most significant biological sensor systems of tissue oxygenation in response to ischemic and inflammatory events. Consequently, pharmacological inhibition of PHD enzymes, leading to stabilization of HIF, may be of considerable therapeutic potential in treating conditions of tissue stress and injury. This Perspective reviews the PHDs and small molecule drug discovery efforts. A critical view of this challenging field is offered, which addresses potential concerns and highlights exciting possibilities for the future.

    Cited By

    This article is cited by 129 publications.

    1. Kento Sonoda, Sudarma Bogahawaththa, Akito Katayama, Saki Ujike, Sae Kuroki, Naho Kitagawa, Kohichi Hirotsuru, Norio Suzuki, Toshio Miyata, Shin-ichi Kawaguchi, Tadayuki Tsujita. Prolyl Hydroxylase Domain Protein Inhibitor Not Harboring a 2-Oxoglutarate Scaffold Protects against Hypoxic Stress. ACS Pharmacology & Translational Science 2022, 5 (5) , 362-372. https://doi.org/10.1021/acsptsci.2c00002
    2. Xiaojin Zhang, Yonghua Lei, Tianhan Hu, Yue Wu, Zhihong Li, Zhensheng Jiang, Changyong Yang, Lianshan Zhang, Qidong You. Discovery of Clinical Candidate (5-(3-(4-Chlorophenoxy)prop-1-yn-1-yl)-3-hydroxypicolinoyl)glycine, an Orally Bioavailable Prolyl Hydroxylase Inhibitor for the Treatment of Anemia. Journal of Medicinal Chemistry 2020, 63 (17) , 10045-10060. https://doi.org/10.1021/acs.jmedchem.0c01161
    3. Amit A. Joharapurkar, Vrajesh B. Pandya, Vishal J. Patel, Ranjit C. Desai, Mukul R. Jain. Prolyl Hydroxylase Inhibitors: A Breakthrough in the Therapy of Anemia Associated with Chronic Diseases. Journal of Medicinal Chemistry 2018, 61 (16) , 6964-6982. https://doi.org/10.1021/acs.jmedchem.7b01686
    4. Yue Wu, Zhensheng Jiang, Zhihong Li, Jing Gu, Qidong You, Xiaojin Zhang. Click Chemistry-Based Discovery of [3-Hydroxy-5-(1H-1,2,3-triazol-4-yl)picolinoyl]glycines as Orally Active Hypoxia-Inducing Factor Prolyl Hydroxylase Inhibitors with Favorable Safety Profiles for the Treatment of Anemia. Journal of Medicinal Chemistry 2018, 61 (12) , 5332-5349. https://doi.org/10.1021/acs.jmedchem.8b00549
    5. Pedro Soares, Morgan S. Gadd, Julianty Frost, Carles Galdeano, Lucy Ellis, Ola Epemolu, Sonia Rocha, Kevin D. Read, and Alessio Ciulli . Group-Based Optimization of Potent and Cell-Active Inhibitors of the von Hippel–Lindau (VHL) E3 Ubiquitin Ligase: Structure–Activity Relationships Leading to the Chemical Probe (2S,4R)-1-((S)-2-(1-Cyanocyclopropanecarboxamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide (VH298). Journal of Medicinal Chemistry 2018, 61 (2) , 599-618. https://doi.org/10.1021/acs.jmedchem.7b00675
    6. Yosuke Ogoshi, Takuya Matsui, Ikuo Mitani, Masahiro Yokota, Masakazu Terashita, Dai Motoda, Kazuhito Ueyama, Takahiro Hotta, Takashi Ito, Yasunori Hase, Kenji Fukui, Katsuya Deai, Hiromi Yoshiuchi, Soichiro Ito, and Hiroyuki Abe . Discovery of JTZ-951: A HIF Prolyl Hydroxylase Inhibitor for the Treatment of Renal Anemia. ACS Medicinal Chemistry Letters 2017, 8 (12) , 1320-1325. https://doi.org/10.1021/acsmedchemlett.7b00404
    7. Saleh Ahmed, Andrew Ayscough, Greg R. Barker, Hannah E. Canning, Richard Davenport, Robert Downham, David Harrison, Kerry Jenkins, Natasha Kinsella, David G. Livermore, Susanne Wright, Anthony D. Ivetac, Robert Skene, Steven J. Wilkens, Natalie A. Webster, and Alan G. Hendrick . 1,2,4-Triazolo-[1,5-a]pyridine HIF Prolylhydroxylase Domain-1 (PHD-1) Inhibitors With a Novel Monodentate Binding Interaction. Journal of Medicinal Chemistry 2017, 60 (13) , 5663-5672. https://doi.org/10.1021/acs.jmedchem.7b00352
    8. John S. Debenham, Christina Madsen-Duggan, Matthew J. Clements, Thomas F. Walsh, Jeffrey T. Kuethe, Mikhail Reibarkh, Scott P. Salowe, Lisa M. Sonatore, Richard Hajdu, James A. Milligan, Denise M. Visco, Dan Zhou, Russell B. Lingham, Dominique Stickens, Julie A. DeMartino, Xinchun Tong, Michael Wolff, Jianmei Pang, Randy R. Miller, Edward C. Sherer, and Jeffrey J. Hale . Discovery of N-[Bis(4-methoxyphenyl)methyl]-4-hydroxy-2-(pyridazin-3-yl)pyrimidine-5-carboxamide (MK-8617), an Orally Active Pan-Inhibitor of Hypoxia-Inducible Factor Prolyl Hydroxylase 1–3 (HIF PHD1–3) for the Treatment of Anemia. Journal of Medicinal Chemistry 2016, 59 (24) , 11039-11049. https://doi.org/10.1021/acs.jmedchem.6b01242
    9. Carles Galdeano, Morgan S. Gadd, Pedro Soares, Salvatore Scaffidi, Inge Van Molle, Ipek Birced, Sarah Hewitt, David M. Dias, and Alessio Ciulli . Structure-Guided Design and Optimization of Small Molecules Targeting the Protein–Protein Interaction between the von Hippel–Lindau (VHL) E3 Ubiquitin Ligase and the Hypoxia Inducible Factor (HIF) Alpha Subunit with in Vitro Nanomolar Affinities. Journal of Medicinal Chemistry 2014, 57 (20) , 8657-8663. https://doi.org/10.1021/jm5011258
    10. Gain Robinson, Mark Zielstorff, Raquel Sevilla, Amy Vanko, Christopher Sinz, Milenko Cimil, Weisheng Zhang, Kimberly Bettano. Multimodal Imaging Reveals that Sustained Inhibition of HIF-Prolyl Hydroxylases Induces Opposing Effects on Right and Left Ventricular Function in Healthy Rats. Molecular Imaging and Biology 2023, 70 https://doi.org/10.1007/s11307-023-01876-9
    11. Chao Shan, YuNing Xia, Zeyu Wu, Jin Zhao. HIF-1α and periodontitis: Novel insights linking host-environment interplay to periodontal phenotypes. Progress in Biophysics and Molecular Biology 2023, 184 , 50-78. https://doi.org/10.1016/j.pbiomolbio.2023.09.002
    12. Pallavi R. Joshi, Shayan Sadre, Xiaoyan A. Guo, Jason G. McCoy, Vamsi K. Mootha. Lipoylation is dependent on the ferredoxin FDX1 and dispensable under hypoxia in human cells. Journal of Biological Chemistry 2023, 299 (9) , 105075. https://doi.org/10.1016/j.jbc.2023.105075
    13. Wenhui Liu, Jian He, Zhimin Li, Shaoping Weng, Changjun Guo, Jianguo He. Oxygen-Sensing Protein Cysteamine Dioxygenase from Mandarin Fish Involved in the Arg/N-Degron Pathway and Siniperca chuatsi Rhabdovirus Infection. Viruses 2023, 15 (8) , 1644. https://doi.org/10.3390/v15081644
    14. Claudia Ferreira, Marie-Françoise J. Doursout, Joselito S. Balingit. Coronavirus Pandemics. 2023, 143-222. https://doi.org/10.1007/978-3-031-10035-2_7
    15. Pedro Soares, Catia Silva, Daniel Chavarria, Filomena S.G. Silva, Paulo J. Oliveira, Fernanda Borges. Drug discovery and amyotrophic lateral sclerosis: Emerging challenges and therapeutic opportunities. Ageing Research Reviews 2023, 83 , 101790. https://doi.org/10.1016/j.arr.2022.101790
    16. Wei Li, Xiaoyu Li, Xunjie Ma, Wei Xiao, Jingjing Zhang. Mapping the m1A, m5C, m6A and m7G methylation atlas in zebrafish brain under hypoxic conditions by MeRIP-seq. BMC Genomics 2022, 23 (1) https://doi.org/10.1186/s12864-022-08350-w
    17. Kaushita Banerjee, Janani Radhakrishnan, Niraikulam Ayyadurai, Ponesakki Ganesan, Numbi Ramudu Kamini. Advances in neoteric modular tissue engineering strategies for regenerative dentistry. Journal of Science: Advanced Materials and Devices 2022, 7 (4) , 100491. https://doi.org/10.1016/j.jsamd.2022.100491
    18. Zixuan Wang, Xiaoyun Chen, Sijia Fan, Chunchun Zhu, Hongyan Deng, Jinhua Tang, Xueyi Sun, Shuke Jia, Qian Liao, Wuhan Xiao, Xing Liu. Methyltransferase SMYD3 impairs hypoxia tolerance by augmenting hypoxia signaling independent of its enzymatic activity. Journal of Biological Chemistry 2022, 298 (12) , 102633. https://doi.org/10.1016/j.jbc.2022.102633
    19. Daisheng Song, Kai Peng, Bradleigh E Palmer, Frank S Lee. The ribosomal chaperone NACA recruits PHD2 to cotranslationally modify HIF ‐α. The EMBO Journal 2022, 41 (22) https://doi.org/10.15252/embj.2022112059
    20. Mai Sugahara, Tetsuhiro Tanaka, Masaomi Nangaku. Future perspectives of anemia management in chronic kidney disease using hypoxia-inducible factor-prolyl hydroxylase inhibitors. Pharmacology & Therapeutics 2022, 239 , 108272. https://doi.org/10.1016/j.pharmthera.2022.108272
    21. Kento Sonoda, Saki Ujike, Akito Katayama, Norio Suzuki, Shin-ichi Kawaguchi, Tadayuki Tsujita. Improving lipophilicity of 5-(1-acetyl-5-phenylpyrazolidin-3-ylidene)-1,3-dimethylbarbituric acid increases its efficacy to activate hypoxia-inducible factors. Bioorganic & Medicinal Chemistry 2022, 73 , 117039. https://doi.org/10.1016/j.bmc.2022.117039
    22. Anna Zuk, Zhihai Si, Sally Loi, Santhosh Bommegowda, Debie Hoivik, Sanjay Danthi, Gyongyi Molnar, Vilmos Csizmadia, Michael Rabinowitz. Preclinical Characterization of Vadadustat (AKB-6548), an Oral Small Molecule Hypoxia-Inducible Factor Prolyl-4-Hydroxylase Inhibitor, for the Potential Treatment of Renal Anemia. Journal of Pharmacology and Experimental Therapeutics 2022, 383 (1) , 11-24. https://doi.org/10.1124/jpet.122.001126
    23. Kaijun Su, Zhihong Li, Linjian Zhang, Shaocong Fang, Mingxuan Mao, Zhuoli Sun, Xiaojin Zhang. Tetrahydropyridin-4-ylpicolinoylglycines as novel and orally active prolyl hydroxylase 2 (PHD2) inhibitors for the treatment of renal anemia. European Journal of Medicinal Chemistry 2022, 238 , 114479. https://doi.org/10.1016/j.ejmech.2022.114479
    24. Hiroki Takano, Akiko Mizuno-Yasuhira, Jun-ichi Yamaguchi, Hiromi Endo. Elucidation of clearance mechanism of TP0463518, a novel hypoxia-inducible factor prolyl hydroxylase inhibitor: does a species difference in excretion routes exist between humans and animals?. Xenobiotica 2022, 52 (7) , 729-741. https://doi.org/10.1080/00498254.2022.2147038
    25. Esmaeil Heydari, Pooya Bagheri, Hossein Zare-Behtash. Photonic-Based Time-Resolved Multipulse Oxygen Sensor. IEEE Sensors Journal 2022, 22 (13) , 12746-12753. https://doi.org/10.1109/JSEN.2022.3177426
    26. Huiqiang Wei, Wenfeng Gou, Jun Gao, Hongxin Ning, Yang Song, Deguan Li, Yong Qin, Wenbin Hou, Yiliang Li. Novel PHD2/HDACs hybrid inhibitors protect against cisplatin-induced acute kidney injury. European Journal of Medicinal Chemistry 2022, 230 , 114115. https://doi.org/10.1016/j.ejmech.2022.114115
    27. Jinghuang Chen, Xingfu Bao, Tian Meng, Jian Sun, Xiurong Yang. Zeolitic imidazolate framework-67 accelerates infected diabetic chronic wound healing. Chemical Engineering Journal 2022, 430 , 133091. https://doi.org/10.1016/j.cej.2021.133091
    28. Mara Mennuni, Roberta Filograna, Andrea Felser, Nina A Bonekamp, Patrick Giavalisco, Oleksandr Lytovchenko, Nils‐Göran Larsson. Metabolic resistance to the inhibition of mitochondrial transcription revealed by CRISPR‐Cas9 screen. EMBO reports 2022, 23 (1) https://doi.org/10.15252/embr.202153054
    29. Guodong Li, Chung-Nga Ko, Dan Li, Chao Yang, Wanhe Wang, Guan-Jun Yang, Carmelo Di Primo, Vincent Kam Wai Wong, Yaozu Xiang, Ligen Lin, Dik-Lung Ma, Chung-Hang Leung. A small molecule HIF-1α stabilizer that accelerates diabetic wound healing. Nature Communications 2021, 12 (1) https://doi.org/10.1038/s41467-021-23448-7
    30. Gregory R. Hughes, Ashley P. Dudey, Andrew M. Hemmings, Andrew Chantry. Frontiers in PROTACs. Drug Discovery Today 2021, 26 (10) , 2377-2383. https://doi.org/10.1016/j.drudis.2021.04.010
    31. Mahesh Kumar Teli, Surendra Kumar, Dharmendra Kumar Yadav, Mi‐hyun Kim. In silico identification of prolyl hydroxylase inhibitor by per‐residue energy decomposition‐based pharmacophore approach. Journal of Cellular Biochemistry 2021, 122 (9) , 1098-1112. https://doi.org/10.1002/jcb.29933
    32. Pierre E. Signore, Guangjie Guo, Zhihua Wei, Weihua Zhang, Al Lin, Ughetta del Balzo, . A small-molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase improves obesity, nephropathy and cardiomyopathy in obese ZSF1 rats. PLOS ONE 2021, 16 (8) , e0255022. https://doi.org/10.1371/journal.pone.0255022
    33. Romain Carcy, Marc Cougnon, Mallorie Poet, Manon Durandy, Antoine Sicard, Laurent Counillon, Nicolas Blondeau, Thierry Hauet, Michel Tauc, Didier F. Pisani. Targeting oxidative stress, a crucial challenge in renal transplantation outcome. Free Radical Biology and Medicine 2021, 169 , 258-270. https://doi.org/10.1016/j.freeradbiomed.2021.04.023
    34. Nicole L. Richardson, Laura J. O'Malley, Daniel Weissberger, Anthony Tumber, Christopher J. Schofield, Renate Griffith, Nicole M. Jones, Luke Hunter. Discovery of neuroprotective agents that inhibit human prolyl hydroxylase PHD2. Bioorganic & Medicinal Chemistry 2021, 38 , 116115. https://doi.org/10.1016/j.bmc.2021.116115
    35. Tao Li, Song Wang, Hao Zhang, Jiankang Yu. The study on the inhibitory mechanism of JTZ-951 and its analogue against prolyl hydroxylase-2 to mediate the response to hypoxia in the process of sports. Molecular Physics 2021, 119 (7) https://doi.org/10.1080/00268976.2020.1853268
    36. Władysław Grzeszczak, Dariusz Szczyra, Mirosław Śnit. Whether Prolyl Hydroxylase Blocker—Roxadustat—In the Treatment of Anemia in Patients with Chronic Kidney Disease Is the Future?. International Journal of Environmental Research and Public Health 2021, 18 (4) , 1612. https://doi.org/10.3390/ijerph18041612
    37. Mahesh Kumar Teli, Surendra Kumar, Dharmendra Kumar Yadav, Mi-hyun Kim. In silico identification of hydantoin derivatives: a novel natural prolyl hydroxylase inhibitor. Journal of Biomolecular Structure and Dynamics 2021, 39 (2) , 703-717. https://doi.org/10.1080/07391102.2020.1714480
    38. Qiyan Zheng, Yahui Wang, Huisheng Yang, Luying Sun, Xinwen Fu, Ruojun Wei, Yu Ning Liu, Wei Jing Liu. Efficacy and Safety of Daprodustat for Anemia Therapy in Chronic Kidney Disease Patients: A Systematic Review and Meta-Analysis. Frontiers in Pharmacology 2021, 11 https://doi.org/10.3389/fphar.2020.573645
    39. Hermann Agis. Targeting the Cellular “Oxygen Sensors”: Hypoxia Pre-conditioning and Stabilization of Hypoxia-Inducible Factors. 2021, 145-177. https://doi.org/10.1007/978-3-319-54586-8_5
    40. Samantha J. Wong, Alison E. Ringel, William Yuan, Joao A. Paulo, Haejin Yoon, Mark A. Currie, Marcia C. Haigis. Development of a colorimetric α-ketoglutarate detection assay for prolyl hydroxylase domain (PHD) proteins. Journal of Biological Chemistry 2021, 296 , 100397. https://doi.org/10.1016/j.jbc.2021.100397
    41. Hiroki Takano, Jun-ichi Yamaguchi, Sota Kato, Makoto Hamada, Mika Tada, Hiromi Endo. Downregulation of CYP1A2, CYP2B6, and CYP3A4 in Human Hepatocytes by Prolyl Hydroxylase Domain 2 Inhibitors via Hypoxia-Inducible Factor- α Stabilization. Drug Metabolism and Disposition 2021, 49 (1) , 20-30. https://doi.org/10.1124/dmd.120.000124
    42. Konstantin Dirscherl, Martin Schläpfer, Birgit Roth Z’graggen, Roland H Wenger, Christa Booy, Renata Flury-Frei, Rita Fatzer, Costica Aloman, Birke Bartosch, Romain Parent, Vartan Kurtcuoglu, Diane de Zélicourt, Donat R. Spahn, Beatrice Beck Schimmer, Erik Schadde. Hypoxia sensing by hepatic stellate cells leads to VEGF-dependent angiogenesis and may contribute to accelerated liver regeneration. Scientific Reports 2020, 10 (1) https://doi.org/10.1038/s41598-020-60709-9
    43. Lennart Brewitz, Anthony Tumber, Inga Pfeffer, Michael A. McDonough, Christopher J. Schofield. Aspartate/asparagine-β-hydroxylase: a high-throughput mass spectrometric assay for discovery of small molecule inhibitors. Scientific Reports 2020, 10 (1) https://doi.org/10.1038/s41598-020-65123-9
    44. Zhihong Li, Shuai Zhen, Kaijun Su, Anthony Tumber, Quanwei Yu, Ying Dong, Michael McDonough, Christopher J. Schofield, Xiaojin Zhang. A small-molecule probe for monitoring binding to prolyl hydroxylase domain 2 by fluorescence polarisation. Chemical Communications 2020, 56 (91) , 14199-14202. https://doi.org/10.1039/D0CC06353C
    45. Menghong Xu, Ping Wang, Suhui Sun, Liquan Gao, Lihong Sun, Lulu Zhang, Jinxia Zhang, Shumin Wang, Xiaolong Liang. Smart strategies to overcome tumor hypoxia toward the enhancement of cancer therapy. Nanoscale 2020, 12 (42) , 21519-21533. https://doi.org/10.1039/D0NR05501H
    46. Mai Sugahara, Tetsuhiro Tanaka, Masaomi Nangaku. Hypoxia-Inducible Factor and Oxygen Biology in the Kidney. Kidney360 2020, 1 (9) , 1021-1031. https://doi.org/10.34067/KID.0001302020
    47. Ernane Souza, Katherine H. Cho, Shelby T. Harris, Naomi R. Flindt, Richard K. Watt, Amy Barton Pai. Hypoxia-inducible factor prolyl hydroxylase inhibitors: a paradigm shift for treatment of anemia in chronic kidney disease?. Expert Opinion on Investigational Drugs 2020, 29 (8) , 831-844. https://doi.org/10.1080/13543784.2020.1777276
    48. Lennart Brewitz, Anthony Tumber, Armin Thalhammer, Eidarus Salah, Kirsten E. Christensen, Christopher J. Schofield. Synthesis of Novel Pyridine‐Carboxylates as Small‐Molecule Inhibitors of Human Aspartate/Asparagine‐β‐Hydroxylase. ChemMedChem 2020, 15 (13) , 1139-1149. https://doi.org/10.1002/cmdc.202000147
    49. Kaijun Su, Zhihong Li, Yancheng Yu, Xiaojin Zhang. The prolyl hydroxylase inhibitor roxadustat: Paradigm in drug discovery and prospects for clinical application beyond anemia. Drug Discovery Today 2020, 25 (7) , 1262-1269. https://doi.org/10.1016/j.drudis.2020.04.017
    50. George Hoppe, Youstina Bolok, Leah McCollum, Jin Zhang, Jonathan E. Sears. Rank Order of Small Molecule Induced Hypoxiamimesis to Prevent Retinopathy of Prematurity. Frontiers in Cell and Developmental Biology 2020, 8 https://doi.org/10.3389/fcell.2020.00488
    51. Jacob T. Bush, Mun Chiang Chan, Shabaz Mohammed, Christopher J. Schofield. Quantitative MS‐Based Proteomics: Comparing the MCF‐7 Cellular Response to Hypoxia and a 2‐Oxoglutarate Analogue. ChemBioChem 2020, 21 (11) , 1647-1655. https://doi.org/10.1002/cbic.201900719
    52. Lennart Brewitz, Anthony Tumber, Christopher J. Schofield. Kinetic parameters of human aspartate/asparagine–β-hydroxylase suggest that it has a possible function in oxygen sensing. Journal of Biological Chemistry 2020, 295 (23) , 7826-7838. https://doi.org/10.1074/jbc.RA119.012202
    53. Mai Sugahara, Shinji Tanaka, Tetsuhiro Tanaka, Hisako Saito, Yu Ishimoto, Takeshi Wakashima, Masatoshi Ueda, Kenji Fukui, Akira Shimizu, Reiko Inagi, Toshimasa Yamauchi, Takashi Kadowaki, Masaomi Nangaku. Prolyl Hydroxylase Domain Inhibitor Protects against Metabolic Disorders and Associated Kidney Disease in Obese Type 2 Diabetic Mice. Journal of the American Society of Nephrology 2020, 31 (3) , 560-577. https://doi.org/10.1681/ASN.2019060582
    54. Zhan Yu, Zhihong Li, Quanwei Yu, Zhi Wang, Huilin Song, Hanyu Sun, Rufeng Fan, Angzhi Bi, Jun Zhang, Xiaojin Zhang. Discovery of prolyl hydroxylase 2 inhibitors with new chemical scaffolds as in vivo active erythropoietin inducers through a combined virtual screening strategy. Chemical Biology & Drug Design 2020, 95 (2) , 270-278. https://doi.org/10.1111/cbdd.13640
    55. Wen-Ning Xu, Huo-Liang Zheng, Run-Ze Yang, Lei-Sheng Jiang, Sheng-Dan Jiang. HIF-1α Regulates Glucocorticoid-Induced Osteoporosis Through PDK1/AKT/mTOR Signaling Pathway. Frontiers in Endocrinology 2020, 10 https://doi.org/10.3389/fendo.2019.00922
    56. Zuo-Lin Li, Yan Tu, Bi-Cheng Liu. Treatment of Renal Anemia with Roxadustat: Advantages and Achievement. Kidney Diseases 2020, 6 (2) , 65-73. https://doi.org/10.1159/000504850
    57. Yao Liu, Fanzheng Meng, Jiabei Wang, Mingyang Liu, Guangchao Yang, Ruipeng Song, Tongsen Zheng, Yingjian Liang, Shugeng Zhang, Dalong Yin, Jizhou Wang, Haiyan Yang, Shangha Pan, Bo Sun, Jihua Han, Jing Sun, Yaliang Lan, Yan Wang, Xirui Liu, Mingxi Zhu, Yifeng Cui, Bo Zhang, Dehai Wu, Shuhang Liang, Yufeng Liu, Xuan Song, Zhaoyang Lu, Jingxuan Yang, Min Li, Lianxin Liu. A Novel Oxoglutarate Dehydrogenase-Like Mediated miR-214/TWIST1 Negative Feedback Loop Inhibits Pancreatic Cancer Growth and Metastasis. Clinical Cancer Research 2019, 25 (17) , 5407-5421. https://doi.org/10.1158/1078-0432.CCR-18-4113
    58. Joseph Ischia, Damien M Bolton, Oneel Patel. Why is it worth testing the ability of zinc to protect against ischaemia reperfusion injury for human application. Metallomics 2019, 11 (8) , 1330-1343. https://doi.org/10.1039/c9mt00079h
    59. Jordan T Noe, Robert A Mitchell. Tricarboxylic acid cycle metabolites in the control of macrophage activation and effector phenotypes. Journal of Leukocyte Biology 2019, 106 (2) , 359-367. https://doi.org/10.1002/JLB.3RU1218-496R
    60. Neil S. Sanghani, Volker H. Haase. Hypoxia-Inducible Factor Activators in Renal Anemia: Current Clinical Experience. Advances in Chronic Kidney Disease 2019, 26 (4) , 253-266. https://doi.org/10.1053/j.ackd.2019.04.004
    61. Gerhard R. Situmorang, Neil S. Sheerin. Ischaemia reperfusion injury: mechanisms of progression to chronic graft dysfunction. Pediatric Nephrology 2019, 34 (6) , 951-963. https://doi.org/10.1007/s00467-018-3940-4
    62. Jolanta Malyszko, Jacek S. Malyszko, Joanna Matuszkiewicz-Rowinska. Hepcidin as a therapeutic target for anemia and inflammation associated with chronic kidney disease. Expert Opinion on Therapeutic Targets 2019, 23 (5) , 407-421. https://doi.org/10.1080/14728222.2019.1599358
    63. Amanda R. Sergesketter, Roger W. Cason, Mohamed M. Ibrahim, Whitney O. Lane, David T. Lubkin, Scott T. Hollenbeck, David A. Brown. Perioperative Treatment with a Prolyl Hydroxylase Inhibitor Reduces Necrosis in a Rat Ischemic Skin Flap Model. Plastic & Reconstructive Surgery 2019, 143 (4) , 769e-779e. https://doi.org/10.1097/PRS.0000000000005441
    64. Dalvir Kular, Iain C. Macdougall. HIF stabilizers in the management of renal anemia: from bench to bedside to pediatrics. Pediatric Nephrology 2019, 34 (3) , 365-378. https://doi.org/10.1007/s00467-017-3849-3
    65. Valeria Cernaro, Giuseppe Coppolino, Luca Visconti, Laura Rivoli, Antonio Lacquaniti, Domenico Santoro, Antoine Buemi, Saverio Loddo, Michele Buemi. Erythropoiesis and chronic kidney disease–related anemia: From physiology to new therapeutic advancements. Medicinal Research Reviews 2019, 39 (2) , 427-460. https://doi.org/10.1002/med.21527
    66. Ben Wielockx, Tatyana Grinenko, Peter Mirtschink, Triantafyllos Chavakis. Hypoxia Pathway Proteins in Normal and Malignant Hematopoiesis. Cells 2019, 8 (2) , 155. https://doi.org/10.3390/cells8020155
    67. Marleen Mayer, Kerstin Fey, Eva Heinze, Christian R. Wick, Martine I. Abboud, Tzu‐Lan Yeh, Anthony Tumber, Nicole Orth, Gunnar Schley, Björn Buchholz, Timothy Clark, Christopher J. Schofield, Carsten Willam, Nicolai Burzlaff. A Fluorescent Benzo[ g ]isoquinoline‐Based HIF Prolyl Hydroxylase Inhibitor for Cellular Imaging. ChemMedChem 2019, 14 (1) , 94-99. https://doi.org/10.1002/cmdc.201800483
    68. A. A. Poloznikov, A. Yu. Khristichenko, N. A. Smirnova, D. M. Hushpulian, I. N. Gaisina, A. I. Osipyants, V. I. Tishkov, I. G. Gazaryan. Structural optimization of adaptaquin, a HIF prolyl hydroxylase inhibitor. Russian Chemical Bulletin 2019, 68 (1) , 168-173. https://doi.org/10.1007/s11172-019-2433-3
    69. Stephanie F. Smith, Sarah A. Hosgood, Michael L. Nicholson. Ischemia-reperfusion injury in renal transplantation: 3 key signaling pathways in tubular epithelial cells. Kidney International 2019, 95 (1) , 50-56. https://doi.org/10.1016/j.kint.2018.10.009
    70. I. N. Gaisina, A. Yu. Khristichenko, A. M. Gaisin, N. A. Smirnova, I. G. Gazaryan, A. A. Poloznikov. Antihypoxic activity of adaptaquin enantiomers. Russian Chemical Bulletin 2018, 67 (12) , 2320-2322. https://doi.org/10.1007/s11172-018-2376-0
    71. Paola Casciato, Nella Ambrosi, Fiorella Caro, Mónica Vazquez, Eduardo Müllen, Adrian Gadano, Eduardo de Santibañes, Martín de Santibañes, Marcos Zandomeni, Magali Chahdi, Julio C. Lazarte, David A. Biagiola, Juan Cruz Iaquinandi, Patricia Santofimia-Castaño, Juan Iovanna, Claudio Incardona, Eduardo Chuluyan. α-lipoic acid reduces postreperfusion syndrome in human liver transplantation - a pilot study. Transplant International 2018, 31 (12) , 1357-1368. https://doi.org/10.1111/tri.13314
    72. Carmen Navarrete, Francisco Carrillo-Salinas, Belén Palomares, Miriam Mecha, Carla Jiménez-Jiménez, Leyre Mestre, Ana Feliú, Maria L. Bellido, Bernd L. Fiebich, Giovanni Appendino, Marco A. Calzado, Carmen Guaza, Eduardo Muñoz. Hypoxia mimetic activity of VCE-004.8, a cannabidiol quinone derivative: implications for multiple sclerosis therapy. Journal of Neuroinflammation 2018, 15 (1) https://doi.org/10.1186/s12974-018-1103-y
    73. Belen Palomares, Francisco Ruiz-Pino, Carmen Navarrete, Inmaculada Velasco, Miguel A. Sánchez-Garrido, Carla Jimenez-Jimenez, Carolina Pavicic, Maria J. Vazquez, Giovanni Appendino, M. Luz Bellido, Marco A. Calzado, Manuel Tena-Sempere, Eduardo Muñoz. VCE-004.8, A Multitarget Cannabinoquinone, Attenuates Adipogenesis and Prevents Diet-Induced Obesity. Scientific Reports 2018, 8 (1) https://doi.org/10.1038/s41598-018-34259-0
    74. Brandon L. Coles-Taylor, Maximilian S. McCallum, J. Scott Lee, Brian W. Michel. Accessing 4-oxy-substituted isoquinolinones via C–H activation and regioselective migratory insertion with electronically biased ynol ethers. Organic & Biomolecular Chemistry 2018, 16 (44) , 8639-8646. https://doi.org/10.1039/C8OB02622J
    75. Taufiq Rahman, Xavier Chee Wezen. Natural Products as Promising Leads Against Oncogenic Transcription Factors and Associated Signalling Pathways. 2018, 55-80. https://doi.org/10.1039/9781782624011-00055
    76. Md. Saiful Islam, Thomas M. Leissing, Rasheduzzaman Chowdhury, Richard J. Hopkinson, Christopher J. Schofield. 2-Oxoglutarate-Dependent Oxygenases. Annual Review of Biochemistry 2018, 87 (1) , 585-620. https://doi.org/10.1146/annurev-biochem-061516-044724
    77. Makoto Hamada, Tetsuo Takayama, Tsuyoshi Shibata, Akira Hiratate, Masato Takahashi, Miyoko Yashiro, Noriko Takayama, Lisa Okumura-Kitajima, Hiroko Koretsune, Hiromitsu Kajiyama, Takumi Naruse, Sota Kato, Hiroki Takano, Hiroyuki Kakinuma. Discovery of novel 2-[(4-hydroxy-6-oxo-2,3-dihydro-1H-pyridine-5-carbonyl)amino]acetic acid derivatives as HIF prolyl hydroxylase inhibitors for treatment of renal anemia. Bioorganic & Medicinal Chemistry Letters 2018, 28 (10) , 1725-1730. https://doi.org/10.1016/j.bmcl.2018.04.039
    78. Hartmut Beck, Mario Jeske, Kai Thede, Friederike Stoll, Ingo Flamme, Metin Akbaba, Jens‐Kerim Ergüden, Gunter Karig, Jörg Keldenich, Felix Oehme, Hans‐Christian Militzer, Ingo V. Hartung, Uwe Thuss. Discovery of Molidustat (BAY 85‐3934): A Small‐Molecule Oral HIF‐Prolyl Hydroxylase (HIF‐PH) Inhibitor for the Treatment of Renal Anemia. ChemMedChem 2018, 13 (10) , 988-1003. https://doi.org/10.1002/cmdc.201700783
    79. Abdollah Amini, Ramin Pouriran, Mohammad-Amin Abdollahifar, Hojjat Allah Abbaszadeh, Seyed Kamran Ghoreishi, Sufan Chien, Mohammad Bayat. Stereological and molecular studies on the combined effects of photobiomodulation and human bone marrow mesenchymal stem cell conditioned medium on wound healing in diabetic rats. Journal of Photochemistry and Photobiology B: Biology 2018, 182 , 42-51. https://doi.org/10.1016/j.jphotobiol.2018.03.010
    80. Shin-ichi Kawaguchi, Yuhei Gonda, Takuya Yamamoto, Yuki Sato, Hiroyuki Shinohara, Yohsuke Kobiki, Atsuhiko Ichimura, Takashi Dan, Motohiro Sonoda, Toshio Miyata, Akiya Ogawa, Tadayuki Tsujita. Furan- and Thiophene-2-Carbonyl Amino Acid Derivatives Activate Hypoxia-Inducible Factor via Inhibition of Factor Inhibiting Hypoxia-Inducible Factor-1. Molecules 2018, 23 (4) , 885. https://doi.org/10.3390/molecules23040885
    81. Olivier Salamin, Tiia Kuuranne, Martial Saugy, Nicolas Leuenberger. Erythropoietin as a performance-enhancing drug: Its mechanistic basis, detection, and potential adverse effects. Molecular and Cellular Endocrinology 2018, 464 , 75-87. https://doi.org/10.1016/j.mce.2017.01.033
    82. Luca Valzania, Kerri L. Coon, Kevin J. Vogel, Mark R. Brown, Michael R. Strand. Hypoxia-induced transcription factor signaling is essential for larval growth of the mosquito Aedes aegypti. Proceedings of the National Academy of Sciences 2018, 115 (3) , 457-465. https://doi.org/10.1073/pnas.1719063115
    83. N. A. Smirnova, A. I. Osipyants, A. Yu. Khristichenko, D. M. Hushpulian, S. V. Nikulin, T. A. Chubar, A. A. Zakhariants, V. I. Tishkov, I. G. Gazaryan, A. A. Poloznikov. HIF2 ODD-luciferase reporter: the most sensitive assay for HIF prolyl hydroxylase inhibitors. Russian Chemical Bulletin 2018, 67 (1) , 150-156. https://doi.org/10.1007/s11172-018-2051-5
    84. 思凡 刘. Design and Synthesis of Proline Hydroxylase Domain Inhibitor. Studies in Synthetic Chemistry 2018, 06 (01) , 1-7. https://doi.org/10.12677/SSC.2018.61001
    85. Tiziana Bruno, Mariacristina Valerio, Luca Casadei, Francesca De Nicola, Frauke Goeman, Matteo Pallocca, Valeria Catena, Simona Iezzi, Cristina Sorino, Agata Desantis, Cesare Manetti, Giovanni Blandino, Aristide Floridi, Maurizio Fanciulli. Che-1 sustains hypoxic response of colorectal cancer cells by affecting Hif-1α stabilization. Journal of Experimental & Clinical Cancer Research 2017, 36 (1) https://doi.org/10.1186/s13046-017-0497-1
    86. Serafim Kiriakidis, Simon S. Hoer, Natalie Burrows, Gloria Biddlecome, Moddasar N. Khan, Cyrille C. Thinnes, Christopher J. Schofield, Norma Rogers, Marina Botto, Ewa Paleolog, Patrick H. Maxwell. Complement C1q is hydroxylated by collagen prolyl 4 hydroxylase and is sensitive to off-target inhibition by prolyl hydroxylase domain inhibitors that stabilize hypoxia-inducible factor. Kidney International 2017, 92 (4) , 900-908. https://doi.org/10.1016/j.kint.2017.03.008
    87. Hirofumi Hitomi, Tomoko Kasahara, Naoko Katagiri, Azusa Hoshina, Shin-Ichi Mae, Maki Kotaka, Takafumi Toyohara, Asadur Rahman, Daisuke Nakano, Akira Niwa, Megumu K. Saito, Tatsutoshi Nakahata, Akira Nishiyama, Kenji Osafune. Human pluripotent stem cell–derived erythropoietin-producing cells ameliorate renal anemia in mice. Science Translational Medicine 2017, 9 (409) https://doi.org/10.1126/scitranslmed.aaj2300
    88. Anna Sonja Müller, Klara Janjić, Bledar Lilaj, Michael Edelmayer, Hermann Agis. Hypoxia-based strategies for regenerative dentistry—Views from the different dental fields. Archives of Oral Biology 2017, 81 , 121-130. https://doi.org/10.1016/j.archoralbio.2017.04.029
    89. Osigbemhe Iyalomhe, Sabina Swierczek, Ngozi Enwerem, Yuanxiu Chen, Monica O. Adedeji, Joanne Allard, Oyonumo Ntekim, Sheree Johnson, Kakra Hughes, Philip Kurian, Thomas O. Obisesan. The Role of Hypoxia-Inducible Factor 1 in Mild Cognitive Impairment. Cellular and Molecular Neurobiology 2017, 37 (6) , 969-977. https://doi.org/10.1007/s10571-016-0440-6
    90. Yue Wu, Zhensheng Jiang, Qidong You, Xiaojin Zhang. Application of in-vitro screening methods on hypoxia inducible factor prolyl hydroxylase inhibitors. Bioorganic & Medicinal Chemistry 2017, 25 (15) , 3891-3899. https://doi.org/10.1016/j.bmc.2017.05.026
    91. Kerri L. Coon, Luca Valzania, David A. McKinney, Kevin J. Vogel, Mark R. Brown, Michael R. Strand. Bacteria-mediated hypoxia functions as a signal for mosquito development. Proceedings of the National Academy of Sciences 2017, 114 (27) https://doi.org/10.1073/pnas.1702983114
    92. Klara Janjić, Christoph Kurzmann, Andreas Moritz, Hermann Agis. Expression of circadian core clock genes in fibroblasts of human gingiva and periodontal ligament is modulated by L-Mimosine and hypoxia in monolayer and spheroid cultures. Archives of Oral Biology 2017, 79 , 95-99. https://doi.org/10.1016/j.archoralbio.2017.03.007
    93. Francesco Locatelli, Lucia Del Vecchio, Maria Carmen Luise. Current and future chemical therapies for treating anaemia in chronic kidney disease. Expert Opinion on Pharmacotherapy 2017, 18 (8) , 781-788. https://doi.org/10.1080/14656566.2017.1323872
    94. Volker H. Haase. Oxygen sensors as therapeutic targets in kidney disease. Néphrologie & Thérapeutique 2017, 13 , S29-S34. https://doi.org/10.1016/j.nephro.2017.01.015
    95. A.A. Poloznikov, A.A. Zakhariants, S.V. Nikulin, N.A. Smirnova, D.M. Hushpulian, I.N. Gaisina, A.G. Tonevitsky, V.I. Tishkov, I.G. Gazaryan. Structure-activity relationship for branched oxyquinoline HIF activators: Effect of modifications to phenylacetamide “tail”. Biochimie 2017, 133 , 74-79. https://doi.org/10.1016/j.biochi.2016.12.004
    96. Hermann Agis. Targeting the Cellular “Oxygen Sensors”: Hypoxia Pre-Conditioning and Stabilization of Hypoxia-Inducible Factors. 2017, 1-33. https://doi.org/10.1007/978-3-319-21056-8_5-1
    97. Mahvash Tavassoli, Yae-eun Suh. Hypoxia in Head and Neck Cancer. 2017, 59-95. https://doi.org/10.1007/978-94-024-1084-6_3
    98. Tzu-Lan Yeh, Thomas M. Leissing, Martine I. Abboud, Cyrille C. Thinnes, Onur Atasoylu, James P. Holt-Martyn, Dong Zhang, Anthony Tumber, Kerstin Lippl, Christopher T. Lohans, Ivanhoe K. H. Leung, Helen Morcrette, Ian J. Clifton, Timothy D. W. Claridge, Akane Kawamura, Emily Flashman, Xin Lu, Peter J. Ratcliffe, Rasheduzzaman Chowdhury, Christopher W. Pugh, Christopher J. Schofield. Molecular and cellular mechanisms of HIF prolyl hydroxylase inhibitors in clinical trials. Chem. Sci. 2017, 8 (11) , 7651-7668. https://doi.org/10.1039/C7SC02103H
    99. Julianty Frost, Carles Galdeano, Pedro Soares, Morgan S. Gadd, Katarzyna M. Grzes, Lucy Ellis, Ola Epemolu, Satoko Shimamura, Marcus Bantscheff, Paola Grandi, Kevin D. Read, Doreen A. Cantrell, Sonia Rocha, Alessio Ciulli. Potent and selective chemical probe of hypoxic signalling downstream of HIF-α hydroxylation via VHL inhibition. Nature Communications 2016, 7 (1) https://doi.org/10.1038/ncomms13312
    100. Patrick R. Arsenault, Daisheng Song, Marian Bergkamp, Andrew M. Ravaschiere, Bradleigh E. Navalsky, Paul M. Lieberman, Frank S. Lee. Identification of Small‐Molecule PHD2 Zinc Finger Inhibitors that Activate Hypoxia Inducible Factor. ChemBioChem 2016, 17 (24) , 2316-2323. https://doi.org/10.1002/cbic.201600493
    Load all citations
    Download PDF

    Pair your accounts.

    Export articles to Mendeley

    Get article recommendations from ACS based on references in your Mendeley library.

    Pair your accounts.

    Export articles to Mendeley

    Get article recommendations from ACS based on references in your Mendeley library.

    You’ve supercharged your research process with ACS and Mendeley!

    STEP 1:
    Click to create an ACS ID

    Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.

    Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.

    Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.

    MENDELEY PAIRING EXPIRED
    Your Mendeley pairing has expired. Please reconnect